Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 11:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 150-Water Clear all
Completed Phase 1 Interventional

Treatment of Orthostatic Hypotension in Autonomic Failure

NCT00223691
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 21, 2026, 11:05 PM EDT
Completed Not applicable Interventional

Dietary Supplementation in Heart Failure

NCT03980574
View directory record Official record
Conditions
Heart Failure
Interventions
R Drink
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 21, 2026, 11:05 PM EDT
Completed Phase 1 Interventional

Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

NCT00136578
View directory record Official record
Conditions
Solid Tumours
Interventions
SB-715992, carboplatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 21, 2026, 11:05 PM EDT
Completed Phase 1Phase 2 Interventional

The Impact of Botox® During Robotic Rehabilitation of the Wrist Following Stroke

NCT01088230
View directory record Official record
Conditions
Stroke
Interventions
Botox®, saline solution
Other
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Sep 21, 2026, 11:05 PM EDT
Terminated Early Phase 1 Interventional Results available

L-citrulline and Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia

NCT03542812
View directory record Official record
Conditions
Infant,Premature, Bronchopulmonary Dysplasia, Pulmonary Hypertension
Interventions
L-Citrulline
Drug
Lead sponsor
University of Utah
Other
Eligibility
14 Days to 3 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 9, 2024 · Synced Sep 21, 2026, 11:05 PM EDT
Recruiting Phase 4 Interventional

Preoperative BOTOX® Injection for Large Ventral Hernia Repair

NCT07220382
View directory record Official record
Conditions
Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional
Interventions
OnabotulinumtoxinA Injection, Saline (placebo) Injection, OnabotulinumtoxinA, 0.9 % Normal Saline, Open Ventral Hernia Repair
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 21, 2026, 11:05 PM EDT
Completed Not applicable Interventional Results available

Pregabalin for the Treatment of Pain After Posterior Spinal Fusions

NCT01366196
View directory record Official record
Conditions
Lumbar Spinal Fusions
Interventions
Pregabalin 150 mg, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
21 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 21, 2026, 11:05 PM EDT
Terminated Phase 2 Interventional Results available

Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

NCT00387894
View directory record Official record
Conditions
Adult Brain Tumors
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
Michael Prados
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Sep 21, 2026, 11:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of CVD 1902 Oral Attenuated Vaccine to Prevent S. Paratyphi A Infection

NCT01129453
View directory record Official record
Conditions
Salmonella
Interventions
CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Sep 21, 2026, 11:05 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

NCT00801931
View directory record Official record
Conditions
Leukemia, Lymphoma, Neuroblastoma, Immunodeficiencies, Anemia
Interventions
Alemtuzumab, Total Body Irradiation, Melphalan, Busulfan, Phenytoin, Fludarabine, Cyclophosphamide, Horse Antithymocyte Globulin, Rabbit Antithymocyte Globulin, Thiotepa
Drug · Radiation
Lead sponsor
Columbia University
Other
Eligibility
Up to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 21, 2026, 11:05 PM EDT
Completed No phase listed Observational

Chemotherapeutic Agents in Brain/Breast

NCT00795678
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
capecitabine, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, lapatinib ditosylate, paclitaxel, vinorelbine ditartrate, Trastuzumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 21, 2026, 11:05 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Characterization of Sympathetic Nerve Activity in Stress Cardiomyopathy

NCT01048125
View directory record Official record
Conditions
Cardiomyopathy
Interventions
Sympathetic Nerve Activity, Mental Stress Test (Color Word Test), The Modified Oxford Technique for Baroreflex Sensitivity, Cold Pressor Test, Echocardiographic evaluation
Device · Behavioral · Drug + 1 more
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 21, 2026, 11:05 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa

NCT00866476
View directory record Official record
Conditions
Shigella
Interventions
CVD 1208S, a Shigella flexneri 2a live, oral vaccine, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Sep 21, 2026, 11:05 PM EDT
Completed Not applicable Interventional

Use of Sterile Water Feeds for Treatment of Hypernatremia in Extremely Low Birth Weight Infants

NCT01219179
View directory record Official record
Conditions
Extremely Low Birth Weight Infants, Hypernatremia
Interventions
Sterile water feedings
Other
Lead sponsor
Case Western Reserve University
Other
Eligibility
24 Hours to 28 Weeks
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Sep 21, 2026, 11:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

NCT03081858
View directory record Official record
Conditions
Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Urinary Bladder, Transitional Cell Carcinoma of the Bladder, Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Urinary Bladder Diseases, Urologic Diseases
Interventions
TSD-001
Drug
Lead sponsor
Lipac Oncology LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Tucson, Arizona • Bakersfield, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 21, 2026, 11:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of a Pre-Workout Dietary Supplement

NCT02952014
View directory record Official record
Conditions
Dietary Modification
Interventions
C4 Extreme, C4 Extreme (without Advantra Z, Placebo
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 40 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 21, 2026, 11:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Cerebrovascular Control

NCT02936687
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo
Drug · Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 17, 2021 · Synced Sep 21, 2026, 11:05 PM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

NCT01436500
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Ifetroban Injection, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 21, 2026, 11:05 PM EDT
Active, not recruiting Phase 2 Interventional Results available

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

NCT03330847
View directory record Official record
Conditions
Metastatic Triple Negative Breast Cancer
Interventions
Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 21, 2026, 11:05 PM EDT
Terminated Phase 2 Interventional Results available

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

NCT01978236
View directory record Official record
Conditions
Melanoma and Brain Metastases
Interventions
Dabrafenib 150 mg, Trametinib 2.0 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 21, 2026, 11:05 PM EDT
Completed Phase 1 Interventional

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

NCT03022409
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Ceralasertib, Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Sep 21, 2026, 11:05 PM EDT
Withdrawn Phase 2 Interventional

Pilot Study to Compare Topical Voriconazole to Placebo as a Pain Reducing Agent

NCT02689713
View directory record Official record
Conditions
Pain, Thermal Injury, Burns, Hyperalgesia
Interventions
Voriconazole (topical), Topical Sterile Water Placebo Group
Drug
Lead sponsor
Kenneth Hargreaves
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Sep 21, 2026, 11:05 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

NCT04020055
View directory record Official record
Conditions
Fabry Disease
Interventions
migalastat HCl 150 mg
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Cleveland, Ohio • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 21, 2026, 11:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution

NCT02751294
View directory record Official record
Conditions
Malaria, Vivax
Interventions
Tafenoquine Control, Tafenoquine dissolution profile X, Tafenoquine SIL
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 21, 2026, 11:05 PM EDT